Evaluation of the clinical remission and its sustainment after discontinuation of infliximab in patients with rheumatoid arthritis who receive "programmed" treatment in randomized controlled trial.

Trial Profile

Evaluation of the clinical remission and its sustainment after discontinuation of infliximab in patients with rheumatoid arthritis who receive "programmed" treatment in randomized controlled trial.

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 12 May 2016

At a glance

  • Drugs Infliximab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms RRRR
  • Most Recent Events

    • 19 Mar 2013 Planned number of patients changed from 400 to 450 as reported by University Hospital Medical Information Network - Japan (Parent trial: UMIN000005113)
    • 05 Apr 2011 New trial record
    • 01 Apr 2011 Status changed from not yet recruiting to recruiting, according to UMIN.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top